Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 72 Strong VictozaⓇ market leadership in Region Latin America Latin America GLP-1 market VictozaⓇ value market share in Latin America GLP-1 value in bDKK VictozaⓇ exenatide dulaglutide Share of total other GLP-1 value diabetes care market share VictozaⓇ exenatide dulaglutide other market 100% 1 0.7 7% 0.6 6% CAGR value¹: 6.7% 80% 73% 0.5 5% 60% 0.4 4% 0.3 3% 40% 0.2 2% 20% 0.1 1% 0.0 0% 0% Feb 2013 Feb 2018 Feb 2013 26% 1% 0% Feb 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT Feb, 2018 value figures (DKK) changing diabetes® Source: IQVIA monthly MAT Feb, 2018 value figures (DKK) novo nordisk

View entire presentation